Mandate

Vinge acts as counsel to Orkla in connection with the acquisition of Health and Sports Nutrition Group

November 21, 2017 EU, Competition and Regulatory

Vinge acts as counsel to Orkla in connection with the acquisition of Health and Sports Nutrition Group HSNG AB (”HSNG”). The seller is Qliro Group AB (publ).

HSNG is a leading actor within e-commerce of health and sport nutrition in the Nordics and runs its business mainly through the internet stores Gymgrossisten.com and Bodystore.com. In addition, Gymgrossisten has physical franchise stores.

Orkla is a leading supplier of branded consumer goods and concept solutions to the grocery, out-of-home and bakery markets in the Nordics, Baltics and selected markets in Central Europe and India. Orkla is listed on the Oslo Stock Exchange and its head office is in Oslo. In 2016, the Group had a turnover of approximately NOK 38 billion, and 18,000 employees at year end.

The transaction is subject to the approval of the relevant competition authorities.

Vinge’s team consists, among others, of responsible partner Peter Sundgren as well as counsel Joacim Rydergård and associates Christina Odengran, Christoffer Nordin, Emelie Håkansson, Mika Jordan, Sara Strandberg, Filip Markhed and Ilze Lukins. Partner Johan Karlsson as well as, among others, associates Trine Osen Bergqvist and Xandra Ståhlberg are advising on competition law issues.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024